# Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

Source: https://onco.cc/trials/nct07750158/  
OnCo record `nct07750158` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of zanzalintinib and pembrolizumab in colorectal cancer, run by Exelixis, now recruiting.

## Summary

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease is a phase 3, randomised interventional study registered as NCT07750158 by Exelixis, with a registry enrolment figure of 600 participants, started 2026-08-25 and due to reach its primary completion in 2030-04-05. Interventions recorded: Zanzalintinib; Pembrolizumab (+) Berahyaluronidase alfa; Placebo. Conditions listed: Colorectal Cancer. Primary outcome: Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the Investigator; DFS in Zanzalintinib Monotherapy Versus Placebo as Assessed by the Investigator. Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of Stage II or III adenocarcinoma of colon or rectum". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: STELLAR-316
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07750158
- Phase: 3
- Setting: Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy
- Sponsor: Exelixis
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT07750158: https://clinicaltrials.gov/study/NCT07750158

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07750158.json